AA
ALDX icon

AlphaCentric Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

AlphaCentric Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2K Buy
37,656
+536
+1% +$921 0.07% 244
2026
Q1 		$62.7K Buy
37,120
+2,208
+6% +$9.67K 0.06% 236
2025
Q4 		$181K Buy
+34,912
New +$179K 0.18% 154
2024
Q4 		$234K Buy
+46,913
New +$241K 0.23% 106

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

AlphaCentric Advisors's ALDX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Aldeyra Therapeutics (ALDX) stake by 1.4% in Q2 2026, buying an estimated $921 and bringing the position to 37,656 shares worth $80.2K. The position accounts for 0.07% of the portfolio, ranked #244.

AlphaCentric Advisors first reported a position in ALDX in Q4 2024 and has held it in 4 quarters since. The position peaked at $234K in Q4 2024. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • AlphaCentric Advisors held 37,656 shares of Aldeyra Therapeutics worth $80.2K as of Q2 2026.
  • AlphaCentric Advisors bought 536 Aldeyra Therapeutics shares in Q2 2026, an estimated $921.
  • Aldeyra Therapeutics made up 0.07% of AlphaCentric Advisors's portfolio in Q2 2026, its #244 holding.
  • AlphaCentric Advisors first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Aldeyra Therapeutics position peaked at $234K in Q4 2024.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.